Slide 1: ANGLE Liquid Biopsy Sample to Answer
ANGLE Liquid Biopsy Sample to Answer Presentation to Shares Andrew Newland & Ian Griffiths 20 February 2018 © ANGLE plc 2018 Page 1
Slide 2: Legal disclaimer
Legal disclaimer LSE AIM: AGL OTCQX: ANPCY This presentation has been prepared by ANGLE plc (the “Company”). By attending this presentation and/or reviewing the slides you agree to be bound by the following conditions. The information and opinions contained in this presentation have not been indepen
Slide 3: Parsortix and Ziplex systems Liquid Biopsy
ParsortixTM and Ziplex® systems Liquid Biopsy Simple blood test for personalised cancer care Proven performance with multiple Key Opinion Leaders Emerging $ multi-billion market (Goldman Sachs $14bn in US alone by 2025) Circulating tumor cell (CTC) solution with strong competitive differentiation Pr
Slide 4: Liquid biopsy improving healthcare and reducing costs: driving precision medicine
Liquid biopsy improving healthcare and reducing costs: driving precision medicine Cancer Research UK: “One in two people born after 1960 in the UK will be diagnosed with some form of cancer during their lifetime.” Each patient’s cancer is different Big pharma developing more selective drugs: Patient
Slide 5: Obtaining cancer cells for analysis
Obtaining cancer cells for analysis Existing approach: solid tumour biopsy Clinicians cut out part of the tumour and analyse the cancer cells − breast cancer mastectomy or lumpectomy − colorectal cancer colonoscopy tumour biopsy − prostate cancer fine needle biopsy and prostatectomy Difficulty in ac
Slide 6: Animation showing Parsortix patented steps
Animation showing ParsortixTM patented steps © ANGLE plc 2018 Page 6
Slide 7: Video showing blood flowing in Parsortix cassette
Video showing blood flowing in ParsortixTM cassette © ANGLE plc 2018 Page 7
Slide 8: Parsortix system – the Complete Picture
ParsortixTM system – the Complete Picture Intact CTCs not just ctDNA Compatible with existing downstream analysis techniques ParsortixTM system captures living cancer cells These cannot be present unless the patient has cancer Evidence-based driven by KOLs and clinical studies Patented product solut
Slide 9: Axela high performance multiplex downstream analysis solution
Axela high performance multiplex downstream analysis solution Ziplex® System − benchtop laboratory platform designed for routine and focused multiplex analysis of protein or RNA biomarkers − sample to answer solution for distributed testing under development HyCEAD chemistry − enables simultaneous m
Slide 10: Far-reaching market potential
Far-reaching market potential Evidence-based approach to prove performance with ovarian cancer, FDA breast cancer Substantiating value as sample collection platform Emerging $ multi-billion market (Goldman Sachs $14bn in US alone by 2025) Partnering strategy for widespread deployment © ANGLE plc 201
Slide 11: Clinical application: ovarian cancer
Clinical application Ovarian studies completed: 400 patients £300 million p.a. market potential 400 patient European (ANG-001) and United Ziplex worked very well with 65 genes in this study States (ANG-003) studies − Medical University of Vienna, Charité and Vivantes Optimisation in progress to impr
Slide 12: Regulatory clearance for clinical use
Regulatory clearance for clinical use Breast cancer FDA clearance progress (400 patient study) Potential to be first FDA cleared system for ANG-002 clinical study commencing shortly harvesting cancer cells from blood − designed to meet FDA regulatory requirements − 200 metastatic breast cancer patie
Slide 13: Clinical application under consideration: metastatic breast cancer biopsy
Clinical application under consideration Non-invasive metastatic breast cancer biopsy £1 billion p.a. market potential CTCs harvested and RNA-Seq analysis successful for 100% of patients (21 patient study) CTCs from Parsortix liquid biopsy had similar patterns of expression for 192 genes to the trad
Slide 14: Clinical application under consideration: prostate biopsy
Clinical application under consideration Non-invasive prostate biopsy £3 billion p.a. market potential Barts Cancer Institute pilot studies − harvested CTCs in 100% of patients (52 patient study) − number of mesenchymal CTCs showed good correlation to Gleason score (80 patient study) Simple blood te
Slide 15: Co-marketing agreement with leading molecular testing company, QIAGEN
Co-marketing agreement with leading molecular testing company, QIAGEN QIAGEN leading molecular testing company − 500,000 customers and $1.3bn revenues − NGS (next generation sequencing), PCR (polymerase chain reaction), single cell analysis products and bioinformatics capabilities Selected Parsortix
Slide 16: Liquid biopsy is coming: advantages of CTCs over ctDNA
Liquid biopsy is coming … Clear advantages of CTCs over ctDNA CTCs allow analysis of DNA, RNA and protein expression −ctDNA only allows analysis of DNA (not RNA and not protein) ANGLE’s ovarian application is based on RNA which cannot be measured by ctDNA CTCs can be analysed individually as single
Slide 17: Financial Highlights for the six months ended October 2017
Financial Highlights for the six months ended 31 October 2017 Six months ended 31 October 2017 2016 Statement of Comprehensive Income £’000 £’000 Comments Revenue 188 219 Research use sales established Cost of sales (54) (43) >145 Parsortix instruments in active use >39,000 blood separations have al
Slide 18: Growing body of published evidence: recent breakthrough results
Growing body of published evidence: recent breakthrough results 10 publications (30 April 2017: 4) and 19 posters (30 April 2017: 13) Barts Cancer Institute megakaryocytes: Parsortix CMS identifies patients 10x more likely to die University of Maryland micro-tentacles allows testing of drugs on livi
Slide 19: Parsortix patented system developing a world-leading position in liquid biopsy
ParsortixTM patented system developing a world-leading position in emerging $ multi-billion liquid biopsy market Providing the Complete Picture (viable, intact CTCs for DNA, RNA, and protein analysis not just ctDNA) − Widespread adoption by leading cancer centres in Europe and the United States FDA
Slide 20: ANGLE plc
ANGLE plc ANGLE Europe Ltd ANGLE North America Inc ANGLE Biosciences Inc 10 Nugent Road 3711 Market Street 50 Ronson Drive, Suite 105 The Surrey Research Park University Science Center 8th floor Toronto Guildford GU2 7AF Philadelphia PA 19104 Ontario M9W 1B3 United Kingdom USA Canada www.ANGLEplc.co